Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-868 Glucose Homeostasis Study in Type 1 Diabetes
NCT05794581Phase 1Completed
- Sponsor
- Carmot Therapeutics
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of acmopatide in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Carmot Therapeutics. Primary endpoint: Area Under the Curve (AUC) in Glucose Metabolism during Mixed Meal Tolerance Test (MMTT). Started Mar 2023; status: completed.
02
Drugs
acmopatide
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05794581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05794581.